EVIDENCE LIBRARY
Chronic Benzodiazepine Claims as a Quality Measure: A Flag Is Not an Individual Verdict
A medication-quality framework counted chronic benzodiazepine use as a safety signal while acknowledging that clinical circumstances can justify it.
A medication-quality framework counted chronic benzodiazepine use as a safety signal while acknowledging that clinical circumstances can justify it.
A claims-based framework
The study applied 19 measures spanning safety, effectiveness, and efficiency to 99,056 older adults using one pharmacy chain in a U.S. state. Chronic benzodiazepine use was identified in 12.8%. The measure described dispensing patterns rather than observed injury or a clinical review of every prescription.
Quality measurement needs exceptions and context
The authors cautioned against treating these measures as explicit rules that settle appropriateness. Claims may omit supplies obtained elsewhere and lack symptom severity, goals, and clinical response. A flagged record can prioritize review, but it cannot by itself demonstrate negligence, dependence, or medication-caused harm. For a specific patient, establish duration, indication, administration, concurrent medicines, and the decision process. Population screening is useful precisely when its limits are kept separate from an individualized clinical conclusion.
Source paper
Original analysis of the supplied journal article, identified as PMC6879678.